Stevanato Group/$STVN
1D1W1MYTD1Y5YMAX
Capital at risk
About Stevanato Group
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
- Ticker
- $STVN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 6,010
- Headquarters
- Piombino Dese, Italy
- Website
- www.stevanatogroup.com
Stevanato Group Metrics
BasicAdvanced
$5.9B
38.08
$0.57
0.74
$0.06
0.29%
Price and volume
Market cap
$5.9B
Beta
0.74
52-week high
$28.00
52-week low
$12.89
Average daily volume
430K
Dividend rate
$0.06
Financial strength
Current ratio
1.613
Quick ratio
1.075
Long term debt to equity
0.206
Total debt to equity
0.288
Dividend payout ratio (TTM)
10.95%
Interest coverage (TTM)
16.13%
Profitability
EBITDA (TTM)
347.347
Gross margin (TTM)
29.42%
Net profit margin (TTM)
10.99%
Operating margin (TTM)
17.67%
Effective tax rate (TTM)
29.99%
Revenue per employee (TTM)
$230,880
Management effectiveness
Return on assets (TTM)
5.45%
Return on equity (TTM)
9.13%
Valuation
Price to earnings (TTM)
38.08
Price to revenue (TTM)
4.158
Price to book
3.8
Price to tangible book (TTM)
4.03
Price to free cash flow (TTM)
-166.183
Free cash flow yield (TTM)
-0.60%
Free cash flow per share (TTM)
-0.13
Dividend yield (TTM)
0.29%
Forward dividend yield
0.29%
Growth
Revenue change (TTM)
7.00%
Earnings per share change (TTM)
0.17%
3-year revenue growth (CAGR)
5.93%
3-year earnings per share growth (CAGR)
-4.11%
What the Analysts think about Stevanato Group
Analyst ratings (Buy, Hold, Sell) for Stevanato Group stock.
Analyst projections of the future price of Stevanato Group stock.
Bulls say / Bears say
High-value solutions grew 16% year-over-year to represent 45% of total revenue in Q2 2026, highlighting robust demand for premium biologics packaging formats (MarketBeat).
Adjusted EBITDA margin expanded to 26% in Q2 2026, up 180 basis points, reflecting operational leverage and efficiency gains from ramp-ups at the Fishers and Latina facilities (MarketBeat).
Management narrowed full-year 2026 guidance to €1.26–€1.28 billion in revenue, €335–€345.2 million in adjusted EBITDA, and diluted EPS of €0.60–€0.62, underscoring confidence in core business momentum despite the Balda divestiture (MarketBeat).
Engineering segment revenue declined 2% in Q2 2026, underscoring ongoing challenges in the equipment and inspection services business (MarketBeat).
Q2 free cash flow was negative €32 million, driven by €52 million in capital expenditures, raising concerns over near-term cash generation and a heavy investment cycle (MarketBeat).
High leverage with net debt of €360.3 million versus €78.6 million in cash at end-Q2 2026 may expose the company to refinancing and interest rate risks (MarketBeat).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Stevanato Group Financial Performance
Revenues and expenses
Stevanato Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Stevanato Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.